Literature DB >> 1352878

Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.

J K Batra1, P G Kasprzyk, R E Bird, I Pastan, C R King.   

Abstract

Immunotoxins were made using five different murine monoclonal antibodies to the human erbB2 gene product and LysPE40, a 40-kDa recombinant form of Pseudomonas exotoxin (PE) lacking its cell-binding domain. All five conjugates were specifically cytotoxic to cancer cell lines overexpressing erbB2 protein. The most active conjugate was e23-LysPE40, generated by chemical crosslinking of anti-erbB2 monoclonal antibody e23 to LysPE40. In addition, a recombinant immunotoxin, e23(Fv)PE40, was constructed that consists of the light-chain variable domain of e23 connected through a peptide linker to its heavy-chain variable domain, which in turn is fused to PE40. The recombinant protein was made in Escherichia coli, purified to near homogeneity, and shown to selectively kill cells expressing the erbB2 protooncogene. To improve the cytotoxic activity of e23(Fv)PE40, PE40 was replaced with a variant, PE38KDEL, in which the carboxyl end of PE is changed from Arg-Glu-Asp-Leu-Lys to Lys-Asp-Glu-Leu and amino acids 365-380 of PE are deleted. The e23(Fv)PE38KDEL protein inhibits the growth of tumors formed by the human gastric cancer cell line N87 in immunodeficient mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352878      PMCID: PMC49398          DOI: 10.1073/pnas.89.13.5867

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  23 in total

1.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

Authors:  V K Chaudhary; J K Batra; M G Gallo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

2.  Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin.

Authors:  C B Siegall; V K Chaudhary; D J FitzGerald; I Pastan
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

Authors:  R M Hudziak; J Schlessinger; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

6.  A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.

Authors:  V K Chaudhary; C Queen; R P Junghans; T A Waldmann; D J FitzGerald; I Pastan
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

7.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

8.  Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).

Authors:  J K Batra; D J Fitzgerald; V K Chaudhary; I Pastan
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 5.069

Review 9.  Recombinant toxins for cancer treatment.

Authors:  I Pastan; D FitzGerald
Journal:  Science       Date:  1991-11-22       Impact factor: 63.714

10.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more
  25 in total

1.  Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays.

Authors:  C Gao; S Mao; C H Lo; P Wirsching; R A Lerner; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 3.  Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies.

Authors:  R R Beerli; W Wels; N E Hynes
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 4.  Preclinical testing of an anti-erbB-2 recombinant toxin.

Authors:  C R King; P G Kasprzyk; P H Fischer; R E Bird; N A Turner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.

Authors:  Daniel A Vallera; Hua Chen; Andrew R Sicheneder; Angela Panoskaltsis-Mortari; Elizabeth P Taras
Journal:  Leuk Res       Date:  2009-03-26       Impact factor: 3.156

6.  New Life for Immunotoxin Cancer Therapy.

Authors:  Raffit Hassan; Christine Alewine; Ira Pastan
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 13.801

7.  Primary T cells for mRNA-mediated immunotoxin delivery.

Authors:  R Eggers; A Philippi; M O Altmeyer; F Breinig; M J Schmitt
Journal:  Gene Ther       Date:  2017-09-22       Impact factor: 4.184

Review 8.  Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.

Authors:  Olga Shilova; Elena Shramova; Galina Proshkina; Sergey Deyev
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

9.  Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.

Authors:  Sangsu Park; Minh Quan Nguyen; Huynh Kim Khanh Ta; Minh Tan Nguyen; Gunsup Lee; Chong Jai Kim; Yeon Jin Jang; Han Choe
Journal:  Int J Mol Sci       Date:  2021-06-17       Impact factor: 6.208

10.  Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.

Authors:  Rafal Zielinski; Ilya Lyakhov; Amy Jacobs; Oleg Chertov; Gabriela Kramer-Marek; Nicholas Francella; Andrew Stephen; Robert Fisher; Robert Blumenthal; Jacek Capala
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.